Cargando…

Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial

OBJECTIVE: The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia. METHODS: One hundred and thirteen patients who were receiving a stable dose of risperidone were randomly assigned to eith...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Jingyuan, Song, Xueqin, Ai, Xiaoqing, Gu, Xiaojing, Huang, Guangbiao, Li, Xue, Pang, Lijuan, Ding, Minli, Ding, Shuang, Lv, Luxian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598102/ https://www.ncbi.nlm.nih.gov/pubmed/26448615 http://dx.doi.org/10.1371/journal.pone.0139717

Ejemplares similares

Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia
por: Ranjbar, Fatemeh, et al.
Publicado: (2015)

Adjunctive treatment with aripiprazole for olanzapine-induced hyperprolactinemia
por: Bise, S., et al.
Publicado: (2022)

Effect of Aripiprazole on Cognitive Function and Hyperprolactinemia in Patients with Schizophrenia Treated with Risperidone
por: Lee, Bong Ju, et al.
Publicado: (2013)

Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels
por: Tasaki, Minami, et al.
Publicado: (2021)

Adjunctive Aripiprazole Versus Placebo for Antipsychotic-Induced Hyperprolactinemia: Meta-Analysis of Randomized Controlled Trials
por: Li, Xianbin, et al.
Publicado: (2013)

Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial
por: Raghuthaman, G., et al.
Publicado: (2015)

Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole
por: Kotorki, Paraskevi, et al.
Publicado: (2010)

Idiopathic granulomatous mastitis associated with risperidone-induced hyperprolactinemia
por: Lin, Chih-Hsun, et al.
Publicado: (2012)

Risperidone Induced Hyperprolactinemia: From Basic to Clinical Studies
por: Stojkovic, Milena, et al.
Publicado: (2022)

Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia
por: Raveendranthan, Dhanya, et al.
Publicado: (2018)

Aripiprazole-induced Hyperprolactinemia in a Young Female with Delusional Disorder
por: Joseph, Sam Padamadan
Publicado: (2016)

Management of risperidone-induced hyperprolactinemia in children: a case report
por: Belhadga, H., et al.
Publicado: (2023)

Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone
por: Hongkaew, Yaowaluck, et al.
Publicado: (2015)

Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial
por: Gupta, Bhanu, et al.
Publicado: (2021)

Efficacy and Safety of Adjunctive Aripiprazole, Metformin, and Paeoniae–Glycyrrhiza Decoction for Antipsychotic-Induced Hyperprolactinemia: A Network Meta-Analysis of Randomized Controlled Trials
por: Zhang, Ling, et al.
Publicado: (2021)

A Comment on “Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia”
por: Naguy, Ahmed
Publicado: (2018)

Risk factors of hyperprolactinemia induced by risperidone and olanzapine and their correlations with plasma glucose and lipids
por: He, Sidi, et al.
Publicado: (2020)

Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia
por: Song, Xueqin, et al.
Publicado: (2014)

Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania
por: Rezayat, Amir Akhavan, et al.
Publicado: (2014)

PM403. Comparison between addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia
por: Lee, Jung Suk, et al.
Publicado: (2016)

A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia
por: Pandey, Ravi S., et al.
Publicado: (2017)

The Short-Term Effects of Risperidone-Induced Hyperprolactinemia on Lipid Metabolism in Drug-Naïve Children and Adolescents
por: Park, Eun Jin, et al.
Publicado: (2015)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
por: Gabriel, Adel
Publicado: (2010)

Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials
por: MENG, Meiling, et al.
Publicado: (2015)

Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study
por: Gianfrancesco, Frank D, et al.
Publicado: (2009)

Effects of Haloperidol, Risperidone, and Aripiprazole on the Immunometabolic Properties of BV-2 Microglial Cells
por: Racki, Valentino, et al.
Publicado: (2021)

Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study
por: Clayton, Anita H, et al.
Publicado: (2014)

Behavioral Mechanisms That Depend on Dopamine and Serotonin in Caenorhabditis elegans Interact With the Antipsychotics Risperidone and Aripiprazole
por: Osuna-Luque, Jaime, et al.
Publicado: (2018)

Hyperprolactinemia
por: Majumdar, Abha, et al.
Publicado: (2013)

Risperidone or Aripiprazole Can Resolve Autism Core Signs and Symptoms in Young Children: Case Study
por: Alsayouf, Hamza A., et al.
Publicado: (2021)

N-Acetylaspartate Reduction in the Medial Prefrontal Cortex Following 8 weeks of Risperidone Treatment in First-Episode Drug-Naïve Schizophrenia Patients
por: Zong, Xiaofen, et al.
Publicado: (2015)

Teratogenicity and hyperprolactinemia
por: Andrade, Chittaranjan
Publicado: (2009)

Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole
por: Remmerie, Bart, et al.
Publicado: (2016)

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)
por: Kelly, Deanna L, et al.
Publicado: (2013)

Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial
por: Garrido-Sánchez, Lucía, et al.
Publicado: (2022)

Pharmacological causes of hyperprolactinemia
por: Torre, Daria La, et al.
Publicado: (2007)

Drug Induced Hyperprolactinemia
por: Venkatanarasu, Ashok, et al.
Publicado: (2021)

Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole
por: Remmerie, Bart, et al.
Publicado: (2016)

The Difference of Fasting Blood Sugar of Male Patients with Schizophrenia Treated with Flexible Dose between Aripiprazole and Risperidone in Medan, Indonesia
por: Marni, Trisna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1aom2o6d4uo12g3dforovr3ftd